auto-injectors may have insufficient needle length to achieve successful intramuscular agent delivery in a number of patients. The Zeneo Ò auto-injector is a novel prefilled, single-use, needle-free device currently in development for intradermal, subcutaneous, and intramuscular agent delivery across a variety of clinical indications. We aimed to evaluate delivery depth of the device calibrated at pressure appropriate for intramuscular (IM) administration.
Methods: This was a prospective single-center study in healthy adult volunteers, in whom each received a single injection of saline into the anterolateral thigh. Using sequential MRI scans, we measured skin-to-muscle distance (STMD) agent delivery depth, and the success of IM agent penetration. Device dynamic pressure measurements were also recorded. specifically designed for self-administration, works via gas propulsion of the drug through micronozzles (250-300 lm diameter) (Fig. 1 ).
Automated drug delivery is triggered by pushing the device onto skin in a simple ''place and push'' approach, with the device mechanisms housed within a protective casing.
By altering the propulsion pressure parameters of the device, which impacts upon the depth of delivery of the chosen agent, the device can be tailored to deliver fixed doses of agents in a range of volumes via the intradermal, subcutaneous performance. Safety data (tolerance and pain assessments) and patient experience data were also collected, and these will be the subject of a subsequent broader report.
METHODS

Study Design and Study Population
This was a single-center study in healthy 
Intervention and Assessments
Subjects returned within 30 days of screening visit for evaluation of device performance. All subjects were under medical supervision during the procedure and for 1 h after the injection. After skin surface antisepsis (with 60% ethanol) all subjects received an injection of 0.9% saline (0.625 ml) into the thigh with the needle-free injector device. Injections were performed by either a trained nurse or by the investigator and applied perpendicular to the skin. During the injection, device dynamic pressure measurements were recorded via a transducer, mounted on the device, from which pressure parameters were obtained, including P init (pressure at 0.7 ms) and P max (maximum pressure after 2 ms).
For each subject, sequential MRI scanning was performed within 7 min of the injection on a 
Data Analysis
Quantitative categorical and continuous variables were described by the number of data, mean ± standard deviation (SD), and range, as appropriate. Differences between groups (men vs women) were calculated using the two-tailed t test for normally distributed data. Principal component analysis (PCA) was performed to identify those factors impacting upon depth of agent delivery.
RESULTS
Baseline Demographic and Clinical Characteristics
A total of 44 subjects received an IM injection.
Of these, four subjects were excluded because of incorrect device technique; in three other subjects, technical difficulties in MRI scans rendered these unsuitable for analysis. As such, a total of 37 subjects with evaluable MRI scans were included in this analysis. Subject characteristics are shown in Table 1 
Skin Thickness
The thickness of different tissue components (dermis and subcutaneous tissues) and the overall STMD are shown in to -5.9, P\0.0001). For both SC thickness and STMD, values were higher in subjects with BMI greater than 25, although these differences were not significant.
Device Pressure and Injection Performance
Across the overall study population, the mean P init was 155 bar (range 140-174 bar) and mean P max was 212 bar (range 187-232 bar). This was within the expected device pressure performance profile. MRI scans were also analyzed to measure delivery and penetration depth of the injectate within muscle (Fig. 2) To develop an explanatory model to explore the impact of key variables on injection depth, we used principal component analysis (PCA).
STMD, P max , BMI, and thigh circumference were all identified as being correlated with injection depth (data not shown) with multivariate linear regression analysis suggesting that P max had the greatest impact on increasing injection depth.
DISCUSSION
In this study, using MRI scanning, we evaluated skin and subcutaneous thickness and STMD at the lateral thigh in healthy volunteers. All measurements were recorded following saline injection via the Zeneo Ò needle-free auto-injector, and as such were performed on tissue subject to tissue compression as a result of device pressure, which represents the clinical conditions in practice. While a number of studies have evaluated skin measurements in different populations using imaging modalities, most have done so using ultrasound [6, 7, 9, [13] [14] [15] and less commonly CT [5, 16] , relatively few studies have used MRI to evaluate STMDs in the thigh, and primarily in children [16] . MRI was used as the imaging modality, as that also allowed assessment of in vivo agent penetration and IM delivery. We are not aware [5] .
In that study, they also evaluated the number of patients with an STMD of greater than 14.3 mm, on the rationale that use of a standard 14.3-mm needle (a frequently used needle length in auto-injector devices) would fail to deliver an IM dose in these patients. They found that while only 2% of men had an STMD greater than 14.3 mm, and were at risk of failure, 42% of women had an STMD exceeding 14.3 mm [5] . Subsequent studies have followed this approach, with greater needle length, and also reported similar concerns. Bhalla et al. evaluated potential risk of IM failure based upon STMD greater than 15.9 mm and reported that 31% were at risk of failure, with women being at far greater risk [7] .
More recently, another US study found that 28% of women had an STMD greater than 15.2 mm, while a UK study found that 68% of patients were at risk of IM failure with a needle length of 15.02 mm [6, 15] .
These data provide the basis for arguing the need for greater needle lengths in devices for IM delivery. This is supported by our study, where we also found relatively high numbers of subjects with STMDs exceeding the needle length of commonly available auto-injectors. In 17 out of 37 subjects (46%), the STMD was greater than 14.3 mm. While only two men (11%) had STMD greater than 14.3 mm, 15 women (83%) had STMD greater than this value; 43% of subjects had an STMD greater than 15.2 mm, 11% of all men and 78% of all women. It should be recognized that the effect of tissue compression in response to forces required to trigger auto-injectors and also subsequent needle propulsion forces may each contribute to agent delivery depth [17] . Data from a porcine model suggests that such forces make a significant contribution to delivery beyond the 14.3-mm needle length [18] .
Nevertheless, it remains that successful IM Fig. 2 MRI scan demonstrating successful intramuscular injectate delivery into vastus lateralis. STMD skin-to-muscle distance delivery with many current injectors of this needle length is uncertain. This is reflected in recommendations from Europe where UK guidance is that a 25-mm needle should be used when administering adrenaline/ epinephrine in anaphylaxis [19] . Furthermore, albeit in the context of vaccination, the Centers for Disease Control and Prevention (CDC) in the USA also recommend use of a 25-mm needle to ensure IM delivery in the thigh [20] .
We also evaluated administration and IM delivery of a test agent (saline) and measured depth of delivery and also delivery success within the thigh muscle. While studies examining this have been performed using animal models [18] , we are not aware of similar studies in humans. We found that use of the Zeneo Ò device, calibrated at pressure appropriate for IM administration, resulted in mean injectate penetration depths of 30.1 mm (range 20.2-45.6 mm) with no meaningful differences between male and female subjects. Additionally, successful IM delivery was reported in 35/37 (95%) of subjects. In those cases of unsuccessful IM delivery, in one subject the injectate traveled the entire STMD and spread on the fascial surface, while in the other case, the injectate traversed the subcutaneous tissue but was directed to a tendon area. This 95% success rate compares favorably with the failure rates extrapolated from the modeling data as reported above [5] [6] [7] 15] . Although exploratory, our analyses suggested that device pressure (P max ) had the greatest influence on injectate penetration. This may be anticipated as the device is designed so as to be capable of delivering to specific tissues for specific indications (i.e., IM or SC) on the basis of pressure settings.
Our study has a number of limitations. Our study population is small, and, because of prespecified inclusion criteria, while over 70% The study was performed in one center in France, and the subjects recruited may not be representative of those from other areas.
Injections were administered by healthcare staff with experience in device use, rather than subject self-administration, and while we do not anticipate lower rates, data is required to show whether the injection depths and IM delivery success will be similar following self-administration. In this study we did not formally analyze the volume of saline delivered within the muscle, and so the proportion of injectate deposited in the more superficial dermal and subcutaneous tissues is unclear. This aspect of the device performance is the subject of further investigation. Finally, in the present study, device use and saline injection were performed directly against naked skin.
However, in the clinical context of adrenaline injection, successful delivery through clothing (e.g., denim) is an essential consideration. 
